HanAll Biopharma has been granted a patent for an anti-FcRn antibody with improved stability, reducing aggregate production while maintaining biological activity. The antibody effectively reduces pathogenic autoantibodies in the blood, making it a promising treatment for autoimmune diseases. GlobalData’s report on HanAll Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights HanAll Biopharma Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on HanAll Biopharma, NSAID cancer drugs was a key innovation area identified from patents. HanAll Biopharma's grant share as of April 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-fcrn antibody with improved stability for autoimmune disease treatment

Source: United States Patent and Trademark Office (USPTO). Credit: HanAll Biopharma Co Ltd

A recently granted patent (Publication Number: US11926669B2) discloses an invention related to an anti-FcRn antibody or its antigen-binding fragment. The antibody comprises specific amino acid sequences in its light and heavy chain variable regions, as outlined in the claims. Additionally, the patent covers the use of this antibody in treating autoimmune diseases, including but not limited to autoimmune neutropenia, multiple sclerosis, rheumatoid arthritis, lupus, and various other conditions.

Furthermore, the patent details methods for producing the anti-FcRn antibody, encoding the antibody's polynucleotide, and formulating a pharmaceutical composition with a pharmaceutically acceptable carrier. The patent also includes guidelines for administering the antibody to a subject in need of treatment for autoimmune diseases, specifying dosages, frequency, and potential side effects to monitor. The patent emphasizes the importance of maintaining specific blood levels of albumin, total cholesterol, and LDL during treatment. Overall, the patent provides a comprehensive framework for utilizing the anti-FcRn antibody in therapeutic applications, particularly in the context of autoimmune diseases in human subjects.

To know more about GlobalData’s detailed insights on HanAll Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies